个人简介：

Tim Xiao, CFA, FRM, is a Principal at Delos Capital since its inception in 2014 and has over 12 years’experience in investment banking and life sciences investment. Tim started his career as an investment banker at China International Capital, and later joined the Investment Banking Division of Goldman Sachs where he completed a series of industry-defining transactions with total deal value over US$4 billion. Tim serves as a Board member for Sichuan Clover, OncoMyx, Liposeuticals, Curatia Medical, Thermalin, and Luqa Pharma and as a Board Observer for Allecra Therapeutics, Intrinsic Therapeutics and Atia Vision.

公司简介：

Delos Capital is a healthcare-focused fund interested in funding and fostering the growth of science and technology across continents and cultures. The firm is interested in the development of drugs and medical devices that address unmet medical needs and enhance existing therapies by making them safer, improving efficacy and lowering costs. Delos is actively working hand-in-hand with the entrepreneurs to bring novel treatments and new devices to market - achieving global success in medicine. The fund's portfolio companies develop solutions in the areas of oncology, infectious diseases, cardiovascular diseases, ophthalmology, orthopedics and bariatrics. It plans to make investments through a broad variety of types and transaction structures, including early and late-stage developments, growth capital, direct or indirect private equity investments, buyout investments, strategic investments, restructurings and recapitalizations and investments in publicly listed securities.

公司官网：http://www.delos.capital/delos/